99% Milnacipran Hcl CAS 101152-94-7  Raw Powder 

Milnepare hydrochloride

Chemical name: (1R, 2S) -rel-2-aminomethyl-N, N-diethyl-1-phenyl cyclopropyl carboxamide hydrochloride

Cas No.:101152-94-7
Molecular formula: C15H23CLN2O.HCL
Molecular weight: 282.81

Charachter: white or almost whitepowder

Suicide and antidepressants
Short-term clinical trials of depression and other psychiatric disorders showed that antidepressants increased suicidal thoughts and committed suicide (suicidal) in children, adolescents and young adults (≤24 years) compared with placebo, risks of. Anyone considering using milnexplatinum or other antidepressants for children, adolescents and young adults (≤24 years of age) must weigh the risks and the clinical needs. Short-term clinical trials did not show that the use of antidepressant drugs in adults older than 24 years of age increased the risk of suicide when compared with placebo, whereas in adults 65 years of age and older, after using antidepressants, suicide The risk of propensity is reduced. Depression and some mental disorders are themselves associated with an increased risk of suicide. The worsening of clinical symptoms, suicidal tendencies, and abnormal behaviors after the onset of antidepressant treatment should be closely observed in all age groups. Family members and caregivers should be advised to closely observe and communicate with their physicians. Milnacipran Hydrochloride is not approved for use in pediatric patients (see [Precautions] - Warnings, Deterioration of Clinical Symptoms and Risk of Suicide).

Indications
Depression treatment.

Dosage
Adult initial dose of 50mg daily, and gradually increased to 100mg daily, 2-3 times a day, after oral administration, according to doctor's advice, according to age and symptoms appropriate to increase or decrease the dose, the need to adjust the dose, refer to the table below Renal function conditions.
The company is located in:

Treatment:
Symptomatic treatment of antidepressants, as with all antidepressants, is usually given after 1-3 weeks of treatment. Drug withdrawal should be gradually reduced withdrawal.
Merger with other psychotropic drugs:
Early treatment can be combined with sedatives and anti-anxiety drugs, to prevent the emergence or aggravation of anxiety symptoms. However, anti-anxiety drugs can not avoid suicide attempts in patients.